is glp 1 for life What Really Happens When You Stop a GLP‑1 in 2026? A One‑Year, Real‑Life Look Beyond the Scale From First Dose to Lasting

Vials are more fragile during transport

In addition, we also found that the clinical rationale and protocol design of the TEXAIS (Treatment With Exenatide in Acute Ischemic Stroke) trial (Trial registration: ClinicalTrials.gov/ANZCTR NTA1127 and ACTRN12614001189617) (108, 109)

Ongoing research aims to develop additional oral GLP-1 medications that may offer improved efficacy and convenience

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

In contrast, and consistent with data from mouse ventricular CMs, we observed that GLP-1(2836) failed to protect hESC-CMs from cytotoxicity under conditions of oxidative stress (Supplemental Figure 4C)